| Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker. | Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
Yang W, Liu Z, Liu T. | 03/13/2024 |
| Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma. | Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma.
Liu T, Li ZZ, Sun L, Yang K, Chen JM, Han XY, Qi LM, Zhou XG, Wang P., Free PMC Article | 10/30/2023 |
| Calcium-activated nucleotides 1 (CANT1)-driven nuclear factor-k-gene binding (NF-kB) signaling pathway facilitates the lung cancer progression. | Calcium-activated nucleotides 1 (CANT1)-driven nuclear factor-k-gene binding (NF-ĸB) signaling pathway facilitates the lung cancer progression.
Gao F, Hu X, Liu W, Wu H, Mu Y, Zhao Y., Free PMC Article | 02/26/2022 |
| Cloning, expression and enzyme activity delineation of two novel CANT1 mutations: the disappearance of dimerization may indicate the change of protein conformation and even function. | Cloning, expression and enzyme activity delineation of two novel CANT1 mutations: the disappearance of dimerization may indicate the change of protein conformation and even function.
Wang HD, Guo LJ, Feng ZQ, Zhang DW, Zhang MT, Gao Y, Chen CL, Zhu BF., Free PMC Article | 07/3/2021 |
| Pseudodiastrophic dysplasia expands the known phenotypic spectrum of defects in proteoglycan biosynthesis. | Pseudodiastrophic dysplasia expands the known phenotypic spectrum of defects in proteoglycan biosynthesis.
Byrne AB, Mizumoto S, Arts P, Yap P, Feng J, Schreiber AW, Babic M, King-Smith SL, Barnett CP, Moore L, Sugahara K, Mutlu-Albayrak H, Nishimura G, Liebelt JE, Yamada S, Savarirayan R, Scott HS., Free PMC Article | 06/26/2021 |
| Knockdown of CANT1 expression can inhibit cell proliferation, migration, and invasion in human clear cell renal cell carcinoma cells, cause cell-cycle arrest in S phase and promote cell apoptosis. | Calcium-activated nucleotidase 1 silencing inhibits proliferation, migration, and invasion in human clear cell renal cell carcinoma.
Liu X, Yang Z, Luo X, Luo J, Fu W, Fang Z, Xia D, Li L, Xu J. | 06/20/2020 |
| CANT1 long non-coding RNA triggers efficient therapeutic efficacy by correcting aberrant long non-coding cascade in malignant uveal melanoma. | CANT1 lncRNA Triggers Efficient Therapeutic Efficacy by Correcting Aberrant lncing Cascade in Malignant Uveal Melanoma.
Xing Y, Wen X, Ding X, Fan J, Chai P, Jia R, Ge S, Qian G, Zhang H, Fan X., Free PMC Article | 02/24/2018 |
| The Multiple Epiphyseal Dysplasia (MED)phenotype is thus allelic to the more severe Desbuquois dysplasia phenotype and the results identify CANT1 as a second locus for recessively inherited MED | MED resulting from recessively inherited mutations in the gene encoding calcium-activated nucleotidase CANT1.
Balasubramanian K, Li B, Krakow D, Nevarez L, Ho PJ, Ainsworth JA, Nickerson DA, Bamshad MJ, Immken L, Lachman RS, Cohn DH., Free PMC Article | 12/2/2017 |
| a novel mutation of CANT1, c.467C>T (p.Ser156Phe) in 3 Indian patients with Desbuquois dysplasia, Kim type from 2 families | A novel CANT1 mutation in three Indian patients with Desbuquois dysplasia Kim type.
Singh A, Kim OH, Iida A, Park WY, Ikegawa S, Kapoor S. | 02/13/2016 |
| Data studied proteoglycan synthesis in CANT1 mutated patient fibroblasts, and found significant reduced GAG synthesis in presence of beta-D-xyloside, suggesting that CANT1 plays a role in proteoglycan metabolism. | Further delineation of CANT1 phenotypic spectrum and demonstration of its role in proteoglycan synthesis.
Nizon M, Huber C, De Leonardis F, Merrina R, Forlino A, Fradin M, Tuysuz B, Abu-Libdeh BY, Alanay Y, Albrecht B, Al-Gazali L, Basaran SY, Clayton-Smith J, Désir J, Gill H, Greally MT, Koparir E, van Maarle MC, MacKay S, Mortier G, Morton J, Sillence D, Vilain C, Young I, Zerres K, Le Merrer M, Munnich A, Le Goff C, Rossi A, Cormier-Daire V., Free PMC Article | 12/8/2012 |
| Novel mutations in the CANT1 gene are reported in three cases of Desbuquois dysplasia type I and fetal hydrops. | Desbuquois dysplasia type I and fetal hydrops due to novel mutations in the CANT1 gene.
Laccone F, Schoner K, Krabichler B, Kluge B, Schwerdtfeger R, Schulze B, Zschocke J, Rehder H., Free PMC Article | 02/18/2012 |
| estimated the age of the founder mutation as approximately 1420 years | A founder mutation of CANT1 common in Korean and Japanese Desbuquois dysplasia.
Dai J, Kim OH, Cho TJ, Miyake N, Song HR, Karasugi T, Sakazume S, Ikema M, Matsui Y, Nagai T, Matsumoto N, Ohashi H, Kamatani N, Nishimura G, Furuichi T, Takahashi A, Ikegawa S. | 09/24/2011 |
| CANT1 is commonly overexpressed in the vast majority of primary prostate carcinomas and in the precursor lesion PIN and may represent a novel prognostic biomarker | The androgen-regulated Calcium-Activated Nucleotidase 1 (CANT1) is commonly overexpressed in prostate cancer and is tumor-biologically relevant in vitro.
Gerhardt J, Steinbrech C, Büchi O, Behnke S, Bohnert A, Fritzsche F, Liewen H, Stenner F, Wild P, Hermanns T, Müntener M, Dietel M, Jung K, Stephan C, Kristiansen G., Free PMC Article | 07/16/2011 |
| The clinical-radiographic spectrum produced by CANT1 mutations must be extended to include Desbuquois dysplasia type 2 and Kim variant. | CANT1 mutation is also responsible for Desbuquois dysplasia, type 2 and Kim variant.
Furuichi T, Dai J, Cho TJ, Sakazume S, Ikema M, Matsui Y, Baynam G, Nagai T, Miyake N, Matsumoto N, Ohashi H, Unger S, Superti-Furga A, Kim OH, Nishimura G, Ikegawa S. | 06/18/2011 |
| Observational study of gene-disease association, gene-gene interaction, gene-environment interaction, and genetic testing. (HuGE Navigator) | Integrative predictive model of coronary artery calcification in atherosclerosis.
McGeachie M, Ramoni RL, Mychaleckyj JC, Furie KL, Dreyfuss JM, Liu Y, Herrington D, Guo X, Lima JA, Post W, Rotter JI, Rich S, Sale M, Ramoni MF., Free PMC Article | 04/7/2010 |
| Mutations in CANT1 in Desbuquois dysplasia are identified. | Identification of CANT1 mutations in Desbuquois dysplasia.
Huber C, Oulès B, Bertoli M, Chami M, Fradin M, Alanay Y, Al-Gazali LI, Ausems MG, Bitoun P, Cavalcanti DP, Krebs A, Le Merrer M, Mortier G, Shafeghati Y, Superti-Furga A, Robertson SP, Le Goff C, Muda AO, Paterlini-Bréchot P, Munnich A, Cormier-Daire V., Free PMC Article | 01/21/2010 |
| human soluble calcium-activated nucleotidase inhibits coagulation in vitro and thrombosis in vivo | Engineered human soluble calcium-activated nucleotidase inhibits coagulation in vitro and thrombosis in vivo.
Yang M, Kirley TL., Free PMC Article | 01/21/2010 |
| The two novel ETV4 fusion partners possess as predominant common characteristics androgen-induction and prostate-specific expression. | Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer.
Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J. | 01/21/2010 |
| The importance of the dimeric state for enzymatic activity and biological function in this nucleotidase by mutating isoleucine 170, is investigated. | Characterization and importance of the dimer interface of human calcium-activated nucleotidase.
Yang M, Horii K, Herr AB, Kirley TL., Free PMC Article | 01/21/2010 |
| Cloning, expression, and characterization of this calcium-acdtivated enzyme, a human enzyme belonging to a new family of extracellular nucleotidases. | Cloning, expression, and characterization of a soluble calcium-activated nucleotidase, a human enzyme belonging to a new family of extracellular nucleotidases.
Smith TM, Hicks-Berger CA, Kim S, Kirley TL. | 01/21/2010 |
| This soluble apyrase is a calcium-binding protein, as evident from saturable Ca2+-dependent changes in intrinsic tryptophan fluorescence, UV difference absorption spectra, and Ca2+-triggered transition from enzymatically inactive form to active enzyme. | Bacterial expression and characterization of a novel, soluble, calcium-binding, and calcium-activated human nucleotidase.
Murphy DM, Ivanenkov VV, Kirley TL. | 01/21/2010 |